Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Current Assets (2016 - 2025)

Historic Current Assets for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $604.3 million.

  • Celldex Therapeutics' Current Assets fell 2240.54% to $604.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $604.3 million, marking a year-over-year decrease of 2240.54%. This contributed to the annual value of $747.2 million for FY2024, which is 7307.65% up from last year.
  • Latest data reveals that Celldex Therapeutics reported Current Assets of $604.3 million as of Q3 2025, which was down 2240.54% from $648.4 million recorded in Q2 2025.
  • Over the past 5 years, Celldex Therapeutics' Current Assets peaked at $835.3 million during Q1 2024, and registered a low of $167.6 million during Q2 2021.
  • In the last 5 years, Celldex Therapeutics' Current Assets had a median value of $410.8 million in 2021 and averaged $471.0 million.
  • In the last 5 years, Celldex Therapeutics' Current Assets skyrocketed by 22458.06% in 2021 and then crashed by 2803.39% in 2023.
  • Celldex Therapeutics' Current Assets (Quarter) stood at $410.8 million in 2021, then fell by 22.67% to $317.7 million in 2022, then surged by 35.88% to $431.7 million in 2023, then skyrocketed by 73.08% to $747.2 million in 2024, then fell by 19.12% to $604.3 million in 2025.
  • Its last three reported values are $604.3 million in Q3 2025, $648.4 million for Q2 2025, and $693.8 million during Q1 2025.